Share
The Knowledge at Wharton Network Acast feed serves as a curated showcase highlighting the best content from our podcast collection. Each week, we feature one standout episode from each show in the Wharton Podcast Network, giving listeners a comprehensive sample of our diverse business and academic content. This rotating selection allows audiences to discover new shows within our network while experiencing the depth and variety of Wharton's thought leadership across different topics and forma ...
…
continue reading
Manage episode 522614465 series 1301267
Content provided by BBC and BBC Radio 4. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BBC and BBC Radio 4 or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Harry Destecroix was studying for his PhD at Bristol University when he co-founded Ziylo. Based on 20 years of Bristol chemistry research, the spin-out company created a new technology that can be developed to treat diabetes more effectively. It's a breakthrough that led to its acquisition by pharmaceutical firm, Novo Nordisk, in a deal reportedly worth up to 600 million pounds. Harry has also founded the incubator, Science Creates and is the founding managing partner of SCVC, a venture capital firm. Harry tells Evan Davis why his own experience of spinning out a company has made him passionate to help other early-stage companies in the Bristol area – whether that’s providing lab space, finance or advice.
(Image: Harry Destecroix Credit: Peter Schiazza, Copyright: Science Creates)
423 episodes
))
